#USA #New York #AVANT BIO #Prix Galien #Intrepid Labs

AVANT BIO and Intrepid Labs Earn Nominations for Prestigious Prix Galien USA Awards

AVANT BIO, a prominent early-stage investment firm, is celebrating its recent nomination for the esteemed Prix Galien USA award in the category of "Incubators, Accelerators and Equity." This recognition is a testament to AVANT BIO's significant commitment to investing in groundbreaking technologies and innovative biological solutions.

In an exciting turn of events, AVANT BIO is not alone in its recognition; its portfolio company, Intrepid Labs, has also garnered a nomination in the fiercely competitive "Best Start Up" category. These nominations are a reflection of both companies' dedication to fostering high-impact initiatives that drive advancements in health and life sciences.

The Prix Galien Awards, established in 1970 by The Galien Foundation, are recognized worldwide for honoring innovations within the life sciences sector. For the 2025 edition, AVANT BIO stands out as one of just 12 nominees in its category, showcasing its influential role in the industry. Intrepid Labs, on the other hand, earned its nomination from a pool of 55 competing startups, illustrating the remarkable quality and potential of its offerings.

As part of this prestigious award ceremony, both AVANT BIO and Intrepid Labs will participate in the Galien Forum business meetings and the Galien Awards Gala to be held in New York this coming October. These events provide an invaluable platform for networking and collaboration with key players and experts throughout the U.S. healthcare sector.

Daniella Kranjac, the founding general partner of AVANT BIO, expressed her gratitude and excitement regarding the nominations. "We are deeply honored to be nominated for the prestigious Prix Galien award. This recognition underscores the value and impact of our investment focus. To be acknowledged alongside such distinguished companies in the industry is both humbling and inspiring," said Kranjac. She also highlighted Intrepid Labs' innovative approaches, specifically their incorporation of artificial intelligence (AI) and robotics which are reshaping drug formulation development, leading to more effective clinical outcomes.

AVANT BIO's investment strategy is aimed at enhancing the discovery, development, and manufacturing processes of therapeutics through cutting-edge technologies. The firm is recognized for its foresight in identifying investment opportunities that promote innovation across various stages of company development. With an eye towards the future, AVANT BIO's goal is to amplify value and unlock the potential within the TechBio and Healthtech sectors.

About AVANT BIO

AVANT BIO is dedicated to funding and nurturing pioneering technologies that are reshaping the landscape of medicine and health. By focusing on critical enabling technologies, AVANT BIO is committed to accelerating new growth and innovation across its portfolio of companies. Their forward-looking investment framework ensures that they not only respond to current trends but also anticipate future developments that will shape health care.

For those interested in learning more about AVANT BIO, potential partnership opportunities, and insights into the latest developments in health technology, more information can be found at AVANT BIO's website. Additionally, followers can keep up with the firm through their LinkedIn page, where industry insights and updates are frequently shared.

The nominations of both AVANT BIO and Intrepid Labs for the Prix Galien USA Awards are not just markers of achievement; they also signify a strong commitment to innovating solutions in life sciences that can profoundly impact patient outcomes and healthcare delivery.

Expect exciting developments from these trailblazing companies in the months ahead as they continue to push the boundaries of what is possible in biotechnological advancements.